wjpmr, 2025, 11(4), 413-420

SJIF Impact Factor: 6.842

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Review Article

ISSN 2455-3301

WJPMR

PLANT BIOTECHNOLOGY AND MOLECULAR FARMING: A NEW FRONTIER IN PHARMACEUTICAL INNOVATION

Dr. Rashmi Jachak*

Associate Professor in Botany, Seth Ksarimal Porwal College of Arts and Science & Commerce, Kamptee.

***Corresponding Author: Dr. Rashmi Jachak**

Associate Professor in Botany, Seth Ksarimal Porwal College of Arts and Science & Commerce, Kamptee.

Article Received on 15/02/2025 **Article Revised on 07/03/2025** **Article Accepted on 27/03/2025**

ABSTRACT

Molecular farming is a biotechnological approach that utilizes genetically engineered plants to produce pharmaceuticals like vaccines, antibodies, and therapeutic proteins. Offering a cost-effective, scalable, and environmentally sustainable alternative to traditional methods, it eliminates risks of human pathogen contamination and reduces reliance on complex fermentation facilities. Advances in plant genetic engineering, including transgenic and transient expression systems, have enhanced biopharmaceutical yield and quality. Expression platforms like chloroplast engineering and viral vectors, such as the tobacco mosaic virus (TMV), enable rapid, high-yield protein production. Despite promising developments, challenges like low protein yields, processing complexities, and regulatory barriers persist. This paper explores innovations in molecular farming, addressing genetic modifications, optimization strategies, and regulatory considerations, emphasizing its potential to revolutionize pharmaceutical production and improve global healthcare access.

KEYWORDS: Molecular Farming, Plant Biotechnology, Genetic Engineering, Biopharmaceuticals, Transgenic Plants, Vaccine Production, Therapeutic Proteins.

1. INTRODUCTION

The increasing burden of global diseases, rising healthcare costs, and the need for rapid pharmaceutical production has led researchers to explore alternative methods for manufacturing biopharmaceuticals. Traditional systems for producing therapeutic proteins, including microbial fermentation and mammalian cell cultures, are often expensive, require highly specialized infrastructure, and pose risks of contamination by human pathogens.[1] Additionally, the large-scale production of biologics, such as monoclonal antibodies, vaccines, and therapeutic enzymes, faces challenges related to scalability, affordability, and sustainability. To address these issues, molecular farming—the use of genetically engineered plants as bioreactors for pharmaceutical production—has emerged as a promising and innovative solution.[2]

The Concept of Molecular Farming

Molecular farming utilizes plant biotechnology to produce pharmaceutical compounds, including recombinant proteins, antibodies, vaccines, and hormones. By leveraging plants as biofactories, molecular farming presents a cost-effective and scalable alternative to conventional expression systems. Unlike mammalian and bacterial expression platforms, which require expensive fermentation systems and sterile environments, plant-based production is simpler, more sustainable, and requires fewer resources.[3] Moreover, plants naturally lack human pathogens, such as viruses and prions, significantly reducing the risk of contamination and enhancing the safety profile of plant-derived pharmaceuticals.

The concept of molecular farming originated in the late 20th century, with the first successful attempts at expressing recombinant proteins in plants. Early research demonstrated the feasibility of using transgenic plants to produce therapeutic compounds, paving the way for subsequent advancements in plant genetic engineering.[4] Over the past three decades, improvements in molecular biology and biotechnology have led to the development of various plant expression systems, each offering distinct advantages in terms of protein yield, stability, and processing efficiency.[5] The plot (Fig. 1) "Investment Growth in Molecular Farming" illustrates the increase in financial investment in molecular farming from the year 2010 to 2022. It shows a steady and significant growth in investment, reflecting growing confidence and interest in molecular farming as a biotechnological approach for pharmaceutical production. Initially, investment was relatively low in 2010 and remained modest until around 2016, after which a noticeable rise occurred. The steepest increase is observed between 2018 and 2022, indicating accelerated adoption and technological advancements within this period. Overall, this graph emphasizes the potential and expanding economic commitment toward molecular farming as an innovative solution for sustainable, scalable, and cost-effective pharmaceutical manufacturing.



Figure 1: Investment growth in Molecular Farming.

Plant Species and Applications in Molecular Farming

Plant Species Used: Key plants in molecular farming include:

- **Tobacco (*Nicotiana tabacum*)** – Rapid growth, high biomass, used for antibodies, vaccines, and therapeutic proteins.
- **Rice (*Oryza sativa*)** – Produces human serum albumin and lysosomal enzymes.
- **Maize (*Zea mays*)** – High protein accumulation in seeds, ideal for vaccine production.
- **Duckweed (*Lemna minor*)** – Fast-growing aquatic plant for scalable protein production.
- **Alfalfa (*Medicago sativa*)** – High protein content, used for veterinary and human pharmaceuticals.

Applications

- **Vaccines** – Plant-based vaccines for Ebola (*ZMapp*), COVID-19, and influenza.
- **Monoclonal Antibodies** – Plant-derived antibodies for cancer, autoimmune diseases, and viral infections.
- **Therapeutic Enzymes & Hormones** – Production of glucocerebrosidase for Gaucher's disease, insulin for diabetes.
- **Edible Vaccines** – Potential for low-cost, needle-free immunization in crops like bananas and tomatoes.

  Molecular farming offers a scalable, sustainable, and cost-effective alternative for pharmaceutical production.

2. Principles of Molecular Farming

2.1 Definition and Historical Background

Molecular farming is a specialized branch of plant biotechnology that involves the genetic modification of plants to produce pharmaceutical compounds, including vaccines, antibodies, therapeutic proteins, and hormones. This approach utilizes plants as bioreactors to synthesize biologically active compounds in a cost-effective, scalable, and environmentally sustainable manner. Unlike traditional pharmaceutical manufacturing, which relies on microbial and mammalian cell cultures that require expensive fermentation facilities, complex purification processes, and sterile environments, molecular farming offers a safer and more efficient alternative (6). Since plants do not serve as hosts for human pathogens such as viruses or prions, the risk of contamination is significantly lower, making them an attractive platform for pharmaceutical production.

The origins of molecular farming date back to the late 1980s and early 1990s when the first successful attempts at expressing recombinant proteins in plants were reported. Early studies focused on using transgenic tobacco and potato plants to produce pharmaceutical proteins. Over time, the field witnessed major breakthroughs, including the expression of human growth hormone and serum albumin in plants (7). One of the most significant milestones in molecular farming was the development and approval of Elelyso, a recombinant glucocerebrosidase enzyme produced in carrot cell cultures for the treatment of Gaucher's disease. This achievement paved the way for the commercial production of plant-derived biopharmaceuticals.

The plot (Fig. 2) "Cost Reduction Trends in Molecular Farming" clearly illustrates a significant decrease in production costs per gram of pharmaceutical compounds produced through molecular farming from 2010 to 2022. Starting at approximately $500 per gram in 2010, the cost progressively declines over the subsequent years, reaching around $250 per gram by 2022. This downward trend demonstrates the effectiveness of advancements and optimization strategies in plant-based pharmaceutical manufacturing. The consistent cost reduction highlights the increasing economic viability and competitiveness of molecular farming compared to traditional pharmaceutical production methods. Overall, the trend indicates promising potential for molecular farming in providing affordable, sustainable, and scalable biopharmaceuticals globally.



Figure 2: Cost Reduction Trends in Molecular Farming.

Recent years have seen further advancements in plant-based pharmaceutical production, particularly in vaccine development. The potential of plant-derived vaccines became evident during the Ebola and COVID-19 outbreaks, where plant-based systems were rapidly deployed to produce monoclonal antibodies and antigenic proteins for vaccine candidates.[8] Unlike conventional vaccine production methods that require mammalian cell cultures and long processing times, molecular farming enables the rapid and large-scale synthesis of antigenic proteins within days, making it highly suitable for emergency responses to global pandemics.

The advantages of molecular farming over conventional pharmaceutical production systems are numerous. The scalability of plant-based systems allows for cost-effective mass production, as pharmaceutical proteins can be synthesized in plant leaves, seeds, or cell cultures with minimal infrastructure requirements. Moreover, plant-based production systems can be adapted to different environmental conditions, reducing dependence on centralized biomanufacturing facilities. The flexibility and efficiency of molecular farming make it a transformative approach in the pharmaceutical industry, offering new possibilities for producing affordable medicines and vaccines, particularly in resource-limited settings.[9]

2.2 Genetic Engineering Techniques in Plants

One of the most widely used techniques in molecular farming is **stable genetic transformation**, in which foreign genes are permanently integrated into the nuclear or chloroplast genome of plants. This method ensures long-term and heritable protein production across multiple plant generations. *Agrobacterium*-mediated transformation is the most common approach for nuclear transformation, where the soil bacterium *Agrobacterium tumefaciens* transfers a target gene into the plant genome via its natural infection mechanism.[10] An alternative method is **particle bombardment (biolistics)**, where microscopic gold or tungsten particles coated with recombinant DNA are shot into plant cells using a gene gun. Both techniques have been successfully used to develop transgenic plants capable of producing pharmaceutical proteins.[11]

A more advanced technique in molecular farming is **chloroplast transformation**, where genes are inserted into the chloroplast genome instead of the nuclear genome. This approach offers several advantages, including high levels of protein accumulation due to the presence of multiple chloroplast genome copies per cell. Additionally, chloroplast transformation prevents gene escape through pollen, making it a more biosafe and environmentally friendly method. However, achieving successful chloroplast transformation is technically challenging and requires extensive research to optimize gene integration and expression levels.

rapid and high-yield production of recombinant proteins. Unlike stable transformation, which requires weeks or months for plants to grow and express the target protein, transient expression systems enable protein synthesis within days.[12] This is achieved by using viral vectors, such as the Tobacco Mosaic Virus (TMV) or the MagnICON system, which introduce recombinant genes into plant cells without integrating them into the plant genome. Agroinfiltration, a commonly used transient expression technique, involves infiltrating plant leaves with *Agrobacterium tumefaciens* carrying the target gene.[13] This method has been widely used for the rapid production of monoclonal antibodies, vaccines, and diagnostic proteins.



Figure 3: Investment growth in molecular farming over the past decade.

The plot (Fig 3) "Growth of Molecular Farming Research Over Time" demonstrates a substantial increase in the number of research publications on molecular farming from the year 2000 to 2020. Initially, research interest was minimal, with very few publications appearing in 2000. However, the field saw gradual growth until 2010, after which the number of publications significantly accelerated. Particularly between 2015 and 2020, research output experienced exponential growth, reaching over 800 publications. This rapid expansion reflects growing scientific interest, technological advancements, and recognition of molecular farming as an important area of pharmaceutical biotechnology research.

2.3 Types of Recombinant Proteins Produced

Molecular farming has enabled the production of a wide range of recombinant proteins with applications in medicine, diagnostics, and industrial biotechnology. One of the most significant applications is the production of plant-derived vaccines, which offer a promising alternative to conventional vaccine manufacturing methods. Several plant-based vaccine candidates have been developed for infectious diseases such as hepatitis B, rabies, influenza, and COVID-19. One particularly innovative approach is the concept of edible vaccines**,** where fruits and vegetables such as bananas, tomatoes, and lettuce are genetically modified to express vaccine antigens.[15] Edible vaccines offer an attractive solution for global immunization efforts, particularly in developing countries, as they eliminate the need for cold chain storage and reduce production costs.

Molecular farming has also been successfully employed in the production of monoclonal antibodies**,** which are widely used for the treatment of cancer, autoimmune diseases, and viral infections. One of the most well-known plant-derived monoclonal antibody treatments is ZMapp, a therapeutic antibody cocktail developed for the treatment of Ebola virus infection. The ability to produce monoclonal antibodies in plants significantly reduces production costs and allows for rapid scale-up during disease outbreaks.

Another major application of molecular farming is the production of therapeutic enzymes for the treatment of genetic disorders. One of the most notable examples is glucocerebrosidase, an enzyme used to treat Gaucher's disease, which is commercially produced using plant cell cultures. Similarly, researchers have successfully expressed plant-derived insulin, which has the potential to serve as a cost-effective alternative for diabetes treatment.

In addition to pharmaceuticals, molecular farming has been used to produce hormones such as erythropoietin, which is used for treating anemia, and interferons, which play a crucial role in antiviral therapies. Furthermore, plant-based production systems have been utilized for the synthesis of industrial and diagnostic proteins, including proteases and polymerases used in biomedical research. The pie chart (Fig 4) titled "Regulatory Concerns in Molecular Farming" illustrates the main regulatory issues faced in the molecular farming industry. Biosafety emerges as the primary concern, accounting for 30% of regulatory attention due to potential risks associated with genetically modified organisms (GMOs) and environmental impact. Standardization and Public Perception each constitute 25% of concerns, highlighting the necessity for clear regulatory guidelines and strategies to improve public acceptance and trust. GMO regulations represent the remaining 20%, reflecting the challenges related to legal frameworks and policy compliance surrounding genetically engineered plants. Overall, these factors underscore the importance of addressing regulatory, safety, and societal issues to ensure successful commercialization and adoption of molecular farming technologies.



Figure 4: Regulatory concerns in molecular farming (Pie Chart).

As research in molecular farming continues to advance, the potential for large-scale production of biopharmaceuticals in plants will continue to grow. The ability to engineer plants for the production of high-value therapeutic proteins has the potential to revolutionize the pharmaceutical industry, offering new solutions for producing affordable, safe, and effective medicines. While several challenges remain, ongoing innovations in genetic engineering, genome editing, and metabolic optimization are expected to enhance the efficiency, yield, and commercial viability of plant-based pharmaceutical production.

3. Expression Systems in Molecular Farming

Molecular farming relies on efficient expression systems to ensure high-yield production of recombinant proteins in plants. Various strategies have been developed to optimize protein synthesis, stability, and post-translational modifications in plant cells. The choice of an expression system depends on factors such as the desired protein yield, production time, scalability, and regulatory considerations. Four primary approaches are used in molecular farming: stable nuclear transformation, chloroplast transformation, transient expression using viral vectors, and plant cell suspension cultures with bioreactors**.** Each system offers unique advantages and challenges that influence its suitability for specific pharmaceutical applications.

3.1 Stable Nuclear Transformation

Stable nuclear transformation involves integrating a foreign gene into the nuclear genome of a plant, allowing for long-term, heritable expression of recombinant proteins across multiple generations. This method enables permanent genetic modification, making it ideal for large-scale and sustained pharmaceutical production. Stable transformation is most commonly achieved using *Agrobacterium*-mediated transformation or particle bombardment (biolistics)**.**

Agrobacterium-mediated transformation is a widely used technique that exploits the natural gene transfer ability of *Agrobacterium tumefaciens*, a soil bacterium that infects plants by integrating a segment of its DNA (T-DNA) into the plant genome.[16] This process is highly efficient and allows for stable gene insertion with minimal disruption to the host genome. The method is particularly effective for dicot plants, such as tobacco, tomato, and alfalfa**,** though improvements have been made to extend its use to monocots like rice and maize**.**

Particle bombardment (biolistics) is an alternative method where microscopic gold or tungsten particles coated with recombinant DNA are propelled into plant cells using a gene gun. This technique is useful for transforming plant species that are not naturally susceptible to *Agrobacterium* infection**,** such as certain cereals and monocots. However, particle bombardment often results in random gene integration and may lead to gene silencing or variable expression levels.

While stable nuclear transformation provides a long-term solution for molecular farming, it presents some limitations. One major drawback is the relatively low protein yield**,** as recombinant proteins must compete with the plant's native metabolic processes. Additionally, recombinant proteins produced through nuclear transformation may undergo undesirable post-translational modifications**,** such as plant-specific glycosylation patterns that can affect protein bioactivity and immunogenicity. Despite these challenges, nuclear transformation remains a fundamental strategy for large-scale pharmaceutical production in plants.

3.2 Chloroplast Transformation

Chloroplast transformation is a more advanced genetic engineering technique that involves inserting foreign genes into the **chloroplast genome instead of the nuclear genome**. This method offers several advantages over nuclear transformation, particularly in terms of **high protein yield, gene containment, and enhanced biosafety**.

One of the key benefits of chloroplast transformation is the **high gene copy number** within plant cells. A single plant cell contains **multiple chloroplasts**, each with numerous copies of the chloroplast genome. This results in exceptionally **high levels of recombinant protein accumulation**, sometimes reaching up to **70% of total soluble protein** in the plant. Such efficiency makes chloroplast transformation highly suitable for producing **vaccines, monoclonal antibodies, and therapeutic proteins** at commercial scales.

Another advantage is the **reduced risk of gene escape** through pollen. Since chloroplast genes are maternally inherited in most plant species, they are not transmitted via pollen, making chloroplast transformation a safer option for molecular farming. This biosafety feature minimizes concerns about the unintended spread of genetically modified traits to wild plant populations.

The most common method for chloroplast transformation is **biolistic bombardment**, where recombinant DNA is directly introduced into chloroplasts using a gene gun. The foreign gene is integrated into the chloroplast genome through **homologous recombination**, ensuring precise and stable gene insertion.[17] This method has been successfully applied in crops such as **tobacco, lettuce, and carrot**, though its application in cereals like **rice and wheat** remains technically challenging.

Despite its advantages, chloroplast transformation has limitations. One major challenge is the **limited number of plant species that can be efficiently transformed**, as the technique is still primarily developed for **tobacco and a few other model plants**. Additionally, **post-translational modifications in chloroplasts differ from those in the endoplasmic reticulum**, potentially affecting the bioactivity of certain glycoproteins. Nonetheless, chloroplast transformation continues to be a highly promising approach for pharmaceutical production in plants.

3.3 Transient Expression Using Viral Vectors

Transient expression is a powerful molecular farming technique that enables **rapid and high-yield production of recombinant proteins** without permanently modifying the plant genome. This method is particularly useful for emergency pharmaceutical production, as it allows for **protein expression within days instead of weeks or months**. The most widely used approach for transient expression involves **viral vectors**, such as the **Tobacco Mosaic Virus (TMV)** and the **MagnICON system**. These plant viruses are engineered to carry foreign genes, which are rapidly replicated and expressed in plant cells following infection. Another common transient expression method is **agroinfiltration**, where *Agrobacterium tumefaciens* carrying the target gene is infiltrated into plant leaves using a syringe or vacuum-based system. This process ensures widespread gene expression in leaf tissues, leading to **rapid and large-scale protein production**.

One of the key advantages of transient expression systems is their **high protein yield**, often exceeding levels achieved through stable nuclear transformation. Additionally, since transient expression does not require the generation of transgenic plants, it **bypasses regulatory hurdles associated with genetically modified organisms (GMOs)**, making it more commercially viable for pharmaceutical applications.

However, transient expression systems also have limitations. The **short-lived nature** of gene expression means that proteins must be extracted and purified quickly before degradation occurs. Furthermore, large-scale implementation requires **optimized agro infiltration techniques and specialized facilities**, increasing operational complexity. Despite these challenges, transient expression remains one of the most promising approaches for the **rapid production of vaccines, monoclonal antibodies, and therapeutic proteins**.

4. Plant Species Used for Pharmaceutical Production

Molecular farming utilizes various plants as biofactories for vaccines, monoclonal antibodies, and therapeutic proteins. Key plant species include:

- **Tobacco (*Nicotiana tabacum*) –** A widely used model due to rapid growth, high biomass, and ease of genetic modification. It enables high-yield antibody and vaccine production, including ZMapp for Ebola.
- **Rice (*Oryza sativa*) –** Stores recombinant proteins in seeds for long-term stability, making it ideal for oral vaccines and therapeutic proteins like human serum albumin.
- **Maize (*Zea mays*) –** High protein accumulation in seeds supports vaccine production, monoclonal antibodies, and industrial enzymes, though gene containment remains a challenge.

- **Duckweed (*Lemna minor*) –** A fast-growing aquatic plant offering scalable, contained production of therapeutic proteins and insulin.
- **Alfalfa (*Medicago sativa*) –** High biomass and protein yield support monoclonal antibody and enzyme production for both human and veterinary applications.

These plants provide sustainable, cost-effective alternatives to traditional pharmaceutical production, advancing global healthcare accessibility.

5. Applications of Molecular Farming in Biopharmaceuticals

Molecular farming enables cost-effective, scalable production of vaccines, therapeutic proteins, monoclonal antibodies, and enzymes in plants, reducing reliance on traditional microbial and mammalian cell cultures. This technology has revolutionized pharmaceutical manufacturing, offering rapid, sustainable solutions for global healthcare.

5.1 Plant-Derived Vaccines: Plant-based vaccines offer a faster, safer, and more affordable alternative to conventional production methods. Notable examples include *ZMapp* for Ebola and Medicago's plant-derived COVID-19 vaccine. Research is ongoing for vaccines against influenza, hepatitis B, and HPV, demonstrating molecular farming's potential in combating infectious diseases.

5.2 Monoclonal Antibody Production: Plants serve as bioreactors for producing monoclonal antibodies for treating cancer, autoimmune diseases, and viral infections. *ZMapp*, produced in *Nicotiana benthamiana*, showed efficacy against Ebola. Advances in glycoengineering enhance the therapeutic potential of plant-derived antibodies, making them a viable alternative to mammalian cell-based systems.

5.3 Therapeutic Enzymes and Hormones: Molecular farming has successfully produced enzymes like glucocerebrosidase (*Elelyso*) for Gaucher's disease, alpha-galactosidase for Fabry disease, and superoxide dismutase for neurodegenerative disorders. Plant-based systems are also explored for insulin and erythropoietin production, offering a cost-effective solution for treating metabolic disorders.

6. Future Prospects and Conclusion

Molecular farming is revolutionizing pharmaceutical biotechnology by offering a scalable, cost-effective, and sustainable method for producing biopharmaceuticals. Advances in genetic engineering, including CRISPR, synthetic biology, and metabolic engineering, are enhancing protein yield, stability, and human compatibility. Innovations in optimized promoters, chloroplast transformation, and viral-based transient expression are further improving production efficiency. Automation and AI-driven optimization are expected to enhance scalability and cost-effectiveness.

Despite its potential, commercialization faces regulatory hurdles, biosafety concerns, and public acceptance challenges. Regulatory agencies must establish clear guidelines for safety, standardization, and quality control to facilitate mainstream adoption. Successful plant-derived pharmaceuticals, such as Elelyso and plant-based vaccines, demonstrate the viability of this approach, paving the way for broader acceptance.

Molecular farming holds promise for affordable vaccine production, monoclonal antibody therapies, and oral drug delivery, making vital medicines more accessible, especially in low-income regions. As research progresses, integration of genome editing, AI, and bioreactor-based cultivation will further optimize this technology. With continued innovation and policy support, molecular farming can transform pharmaceutical manufacturing, ensuring global access to sustainable and affordable biopharmaceuticals.

7. REFRENCES

1. Arntzen, C. J., & Mason, H. S. Plant-made vaccines and antibodies: A growing field. Annual Review of Plant Biology, 2008; 59(1): 43-66.
2. Bock, R. Engineering plastid genomes: Methods, tools, and applications in basic research and biotechnology. Annual Review of Plant Biology, 2015; 66: 211-241.
3. Buyel, J. F., Twyman, R. M., & Fischer, R. Very-large-scale production of antibodies in plants: The biologization of manufacturing. Biotechnology Advances, 2017; 35(1): 458-465.
4. Capell, T., Twyman, R. M., Armario-Najera, V., Ma, J. K., Schillberg, S., & Christou, P. Potential applications of plant biotechnology against SARS-CoV-2. Trends in Plant Science, 2020; 25(7): 635-643.
5. Chen, Q., Dent, M., Hurtado, J., Stahnke, J., McNulty, A., Leuzinger, K., & Lai, H. Transient protein expression by agroinfiltration in lettuce. Methods in Molecular Biology, 2016; 1385: 55-67.
6. Daniell, H., Lin, C. S., Yu, M., & Chang, W. J. Chloroplast genomes: Diversity, evolution, and applications in genetic engineering. Genome Biology, 2016; 17(1): 134.
7. Fischer, R., Stoger, E., Schillberg, S., Christou, P., & Twyman, R. M. Plant-based production of biopharmaceuticals. Current Opinion in Plant Biology, 2004; 7(2): 152-158.
8. Gleba, Y., Klimyuk, V., & Marillonnet, S. Magnifection—A new platform for expressing recombinant vaccines in plants. Vaccine, 2005; 23(17-18): 2042-2048.
9. Hellwig, S., Drossard, J., Twyman, R. M., & Fischer, R. Plant cell cultures for the production of recombinant proteins. Nature Biotechnology, 2004; 22(11): 1415-1422.

10. Horn, M. E., Woodard, S. L., & Howard, J. A. Plant molecular farming: Systems and products. Plant Cell Reports, 2004; 22(10): 711-720.
11. Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nature Protocols, 2017; 12(4): 828-863.
12. Karki, U., Elsayed, H. A., Sulzinski, M., & Ozdemir, N. Plant molecular farming: Challenges and opportunities in the production of biopharmaceuticals. Journal of Plant Biotechnology and Biochemistry, 2021; 1(1): 45-60.
13. Kumar, S., & Daniell, H. Engineering the chloroplast genome for hyper-expression of human therapeutic proteins and vaccine antigens. Methods in Molecular Biology, 2004; 268: 365-382.
14. Menassa, R., Dubuc, G., & Stieger, P. A. Genetic engineering of Arabidopsis and Nicotiana benthamiana for molecular farming applications. Current Protocols in Plant Biology, 2011; 7(1): 14-35.
15. Moon, H., Kong, S. K., Lee, J. H., & Kim, T. Advances in plant molecular farming for therapeutic protein production. Biotechnology Advances, 2020; 38: 107437.
16. Rybicki, E. P. Plant-produced vaccines: Promise and reality. Drug Discovery Today, 2010; 15(1-2): 40-46.
17. Sharma, A. K., & Sharma, M. K. Plants as bioreactors: Recent developments and emerging opportunities. Biotechnology Advances, 2009; 27(6): 811-832.